he Board of Directors of Amarillo Biosciences, Inc. AMARILLO, Texas, April 14 /PRNewswire/ -- Amarillo Biosciences, Inc. (Nasdaq: AMAR) today announced that Richard Franco, Chairman/CEO and co-founder of LipoMed, Inc. of Raleigh, North Carolina has been nominated to serve on the Board of Directors of Amarillo Biosciences. Mr. Franco was formerly president of The Richards Groups LTD of Raleigh and President/CEO of Trimeris, Inc. of Research Triangle Park. Mr. Franco has held senior management posts at Eli Lilly & Company and Glaxo, Inc. and served as a director of Entremed, Inc. in Rockville, Maryland. Dr. Edward Amento, Director and Chairman of the Molecular Medicine Research Institute, Mountain View, California also has been nominated for a board position. Dr. Amento was formerly the President and co-founder of Connective Therapeutics (now Connectics Corp.) of Palo Alto, California. Dr. Amento held senior positions at Genentech from 1987 to 1993. Prior to joining Genentech, Dr. Amento held various teaching and research positions at Harvard Medical School. Currently, Dr. Amento is clinical professor of medicine and dermatology at Stanford University School of Medicine. "We are delighted that Mr. Richard Franco and Dr. Edward Amento have consented to serve on our Board of Directors," said Dr. Joseph M. Cummins, President and CEO. "Upon election, they will begin serving after our annual shareholder's meeting, May 11, 1999. They will add vast and diverse experience to our Board." Founded in 1984, Amarillo Biosciences is a world leader in the development of low dose oral interferon alpha as a treatment for a variety of conditions including Sjogren's syndrome, fibromyalgia, opportunistic infections in patients who are HIV positive, hepatitis B and hepatitis C. Interferon plays a critical role in immune system modulation. High dosage injectable interferon is currently used for the treatment of cancer, multiple sclerosis and hepatitis in humans. Amarillo Biosciences is an emerging biopharmaceutical company incorporated in 1984 and dedicated to the development of oral and topical applications of low dose interferon for human and animal health applications. Low dose interferon has the potential to be less costly and to have fewer side effects than high dose injectable interferon. SOURCE Amarillo Biosciences, Inc. /CONTACT: Kathleen L. Kelleher, COO and Vice President, Business Development of Amarillo Biosciences, Inc., 806-376-1741, or email, ABI@AmarBio.com/ /Company News On-Call: http://www.prnewswire.com/comp/118055.html or fax, 800-758-5804, ext. 118055/ /Web site: http://www.amacell.com/ (AMAR) CO: Amarillo Biosciences, Inc. ST: Texas IN: MTC SU: PER
MR. RICHARD FRANCO AND DR. EDWARD AMENTO ARE NEW CANDIDATES FOR
Press spacebar to pause and continue. Press esc to stop.